PT Indofarma Tbk (ISX:INAF) Research & Development: Rp0 Mil (TTM As of Dec. 2025)


ISX:INAF PT Indofarma Tbk ISX:INAF
8 GF Score
Price Rp126.00
GF Value Rp176.99
! 6 Warning Signs
View Full Analysis

What is PT Indofarma Tbk Research & Development?

PT Indofarma Tbk ISX:INAF 8 Research & Development is Rp0 Mil as of Dec. 2025. GuruFocus rates ISX:INAF with a GF Score™ of 8/100 and a GF Value™ of Rp176.99. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PT Indofarma Tbk's Research & Development for the three months ended in Dec. 2025 was Rp0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was Rp0 Mil.

PT Indofarma Tbk  (ISX:INAF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PT Indofarma Tbk Research & Development Related Terms

PT Indofarma Tbk Research & Development Historical Data

* Premium members only.

The historical data trend for PT Indofarma Tbk's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Indofarma Tbk Research & Development Chart

PT Indofarma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PT Indofarma Tbk Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ISX:INAF
8GF Score
PT Indofarma Tbk ISX:INAF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Indofarma Tbk Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of Rp0 Mil mean?
PT Indofarma Tbk (ISX:INAF) has a Research & Development of Rp0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's Research & Development too high?
PT Indofarma Tbk's current Research & Development is Rp0 Mil. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's Research & Development compare to ZTS and VTRS?
PT Indofarma Tbk's Research & Development of Rp0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PT Indofarma Tbk and its competitors. PT Indofarma Tbk's current Research & Development is Rp0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current Research & Development of Rp0 Mil. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current Research & Development is Rp0 Mil. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current Research & Development is Rp0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued. The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.

Key valuation signals for ISX:INAF:

  • Research & Development: Rp0 Mil
  • GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
  • GF Score™: 8/100 with 6 warning signs

No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Indofarma Tbk Business Description

Address Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score

Get the complete analysis for ISX:INAF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp126.00
Price
Rp176.99
GF Value